- Q1 2024 Cardiff Oncology Inc Earnings Call TranscriptMay 02, 2024€3.9 (-3.35%)Earnings
- Q4 2023 Cardiff Oncology Inc Earnings Call TranscriptFeb 29, 2024€1.64 (+2.24%)Earnings
- Q3 2023 Cardiff Oncology Inc Earnings Call TranscriptNov 02, 2023€0.994 (+2.05%)Earnings
- Cardiff Oncology Inc Clinical Update Call TranscriptSep 26, 2023
- Cardiff Oncology Inc Clinical and Corporate Update Call TranscriptAug 07, 2023
- Cardiff Oncology Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Cardiff Oncology Inc at Cowen Health Care Conference- GI/GU Oncology Panel TranscriptMar 07, 2023
- Cardiff Oncology Inc at JMP Securities Hematology Oncology Summit (Virtual) TranscriptDec 07, 2022
- Cardiff Oncology Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Cardiff Oncology Inc to Provide a Clinical and Corporate Update Call TranscriptSep 12, 2022
- Cardiff Oncology Inc to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer at ASCO-GI TranscriptJan 18, 2022
- Cardiff Oncology Inc to Discuss New Data from Lead Clinical Program in KRAS-mutated mCRC Webinar TranscriptSep 08, 2021
- Cardiff Oncology Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Cardiff Oncology Inc KOL Webinar TranscriptApr 12, 2021
- Cardiff Oncology Inc Discusses KRAS Mutations in Cancer TranscriptOct 14, 2020
- Cardiff Oncology, Inc. - Special Call TranscriptSep 23, 2020
- Cardiff Oncology Inc Onvansertib Clinical Trials TranscriptMay 18, 2020
- Trovagene Inc at Needham Healthcare Conference TranscriptApr 15, 2020
- Trovagene Inc Business Update Conference Call TranscriptJun 07, 2019
Cardiff Oncology Inc at William Blair Biotech Focus Conference (Virtual) Transcript
So this is our second day of the Biotech Focus Conference. So we are really privileged to have the CEO of Cardiff Oncology, Mark Erlander, to give us a little debrief about the progress that you've made. Obviously the KRAS space is really hot, and it seems like the activity of this compound has pan-cancer activity. So we're really excited to hear what you have to say. But before we do that, I have to disclose that for a full list of conflicts and disclosures, please go to our website, WilliamBlair.com, for a list of full disclosures.
Questions & Answers
So to start off, Mark, maybe it's been a great year for the Company. So maybe reflect on the past year and highlight some points for us, all the accomplishments, and what are you looking forward to in the next year, year and a half for the Company?
Thank you. Thank you, Andy. And look, we are absolutely thrilled to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)